LP
DAWN

LMR Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

LMR Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.78M Buy
+362,641
New +$5.11M 0.02% 504
2021
Q3 		– Sell
-50,000
Closed -$1.14M – 1035
2021
Q2 		$1.14M Buy
+50,000
New +$1.04M 0.02% 497

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

LMR Partners's DAWN Position: Q1 2026 in Review

LMR Partners opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 362,641 shares worth $7.78M. The stake represents 0.02% of the portfolio and ranks #504 among its holdings. This is a return to the name: LMR Partners previously reported a position in DAWN as recently as Q2 2021.

LMR Partners first reported a position in DAWN in Q2 2021 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • LMR Partners held 362,641 shares of Day One Biopharmaceuticals worth $7.78M as of Q1 2026.
  • Day One Biopharmaceuticals was a new LMR Partners position in Q1 2026.
  • Day One Biopharmaceuticals made up 0.02% of LMR Partners's portfolio in Q1 2026, its #504 holding.
  • LMR Partners first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.